Vulvovaginal Candidiasis

May 06, 2022

Jack D. Sobel, MD, examines the efficacy and safety of oteseconazole in reducing the incidence of recurrent vulvovaginal candidiasis in patients.

April 29, 2022

The US Food and Drug Administration has approved oteseconazole (Vivjoa; Mycovia Pharmaceuticals) to reduce the incidence of recurrent vulvovaginal candidiasis.

April 22, 2022

Vulvovaginal candidiasis (VVC)—commonly known as a yeast infection—is a problem many women face at some point. About half of all women have had at least 1 of these infections clinical diagnosed, and between 6% and 10% are believed to develop a recurrent form of this condition with 3 to 4 or more episodes in a single year, according to a new report.

April 14, 2022

The VMB may be a biological barrier to pathogenic microorganisms. There is also an increased risk of acquiring various vaginal pathogens when the dominant lactobacilli community is disrupted.

April 14, 2022

Women with bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) were significantly less likely to use intimate soap and moist wipes after urination compared to healthy women without any vulvovaginal symptoms, according to a cross-sectional study published in the journal Revista Brasileira de Ginecologia e Obstetricia.

April 14, 2022

Not only does vulvodynia impact a woman’s sexual and psychological health, but it also places significant financial burden on those seeking treatment.

March 22, 2022

Using bactericidal soaps and sex toys and having anal sex were associated with higher rates of bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), according to a study in RBGO Gynecology and Obstetrics (Revista Brasileira de Ginecologia e Obstetricia). However, study authors caution, identifying these associations do not establish causality.

March 22, 2022

A study published in Women’s Health Reports suggests best practices for treating recurrent vulvovaginal candidiasis.

March 22, 2022

The incidences of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are especially high in young women, and women with a limited education and low-family income, according to a nationwide cohort study in the International Journal of Infectious Diseases.

March 04, 2022

The incidences of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are especially high in young women, and women with a limited education and low-family income, according to a nationwide cohort study in the International Journal of Infectious Diseases.